School of Medicine
Showing 51-100 of 427 Results
-
Kung Chun Chiu
Postdoctoral Scholar, Pathology
BioI studied the tumor microenvironment of liver cancer during my graduate training in Hong Kong. Here at Stanford, I am using different genome editing tools and mouse models to investigate the role of macrophages in promoting tumor progression and immune tolerance in liver cancer. Our findings indicate that tumor associated macrophages including Kupffer cells, have a profound impact on liver cancer and I am studying the molecular basis for these effects.
-
Michael Cleary
Lindhard Family Professor of Pediatric Cancer Biology and Professor of Pathology, Emeritus
Current Research and Scholarly InterestsThe role of oncoproteins in cancer and development; molecular and cellular biology of hematologic malignancies; targeted molecular therapies of cancer.
-
Laetitia Coassolo (Voilquin)
Postdoctoral Scholar, Pathology
BioI received my PharmD from the University of Strasbourg (France) in 2018. I completed my PhD in Oncology and Cell Biology in 2020 in Dr. Catherine Tomasetto's group in IGBMC (France) studying cell metabolism and cell signaling in breast cancer. I am now a postdoctal fellow in Dr. Katrin Svensson lab and I am highly interested in understanding the molecular mechanisms of non-classical hormones in metabolic diseases.
-
Maria Inmaculada Cobos Sillero
Assistant Professor of Pathology
Current Research and Scholarly InterestsOur lab uses cellular and molecular methods, single-cell technology, and quantitative histology to study human neurodegenerative diseases. Current projects include:
- Using single-cell RNA-sequencing to understand selective vulnerability and disease progression in human Alzheimer’s disease brain
- Investigating mechanisms of tau-related neurodegeneration in human brain
- Studying the neocortical and limbic systems in Diffuse Lewy Body Disease (DLBD) at the single cell level -
Le Cong
Assistant Professor of Pathology (Pathology Research) and of Genetics
BioDr. Cong's group is developing novel genome technology for genome engineering and single-cell genomics, leveraging scalable computational methods. His group has several focus areas. We are using genome technology such as gene-editing and data science method/analysis to study immunological and neurological diseases. His work has led to one of the first CRISPR/Cas9 gene-editing tools for in vivo gene therapy. More recently, his group invented tools for cleavage-free large gene insertion via mining microbial recombination protein, and developed single-cell tracking approach for studying cancer biology and cancer immunology. Dr. Cong is a recipient of the NIH/NHGRI Genomic Innovator Award, a Baxter Foundation Faculty Scholar, and has been selected by Clarivate Web of Science as a Highly Cited Researcher.
-
Joanne Cornbleet
Associate Professor of Pathology at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsAs medical director of the Hematology Laboratory, my main focus is service work, including laboratory administration, bone marrow pathology, and flow cytometry interpretation. Publications arise primarily from development or evaluation of laboratory methods or collections of unusual patient cases.
-
Helio Costa
Adjunct Clinical Assistant Professor, Pathology
BioHelio Costa, PhD, is a medical geneticist with expertise in oncology, medical genetics and genomics, computational biology, data science, software engineering, and product development. He is passionate about leveraging his interdisciplinary skillset to build and develop commercial-grade cancer diagnostic products and medical software that aid in patient care and clinical decision support. Currently he is Medical Director of Oncology at Natera, and an Adjunct Clinical Assistant Professor in the Department of Pathology at Stanford Medical School.
Dr. Costa's research focuses on developing and implementing new medical diagnostic genetic tests and software for use in patient care. His research group developed DNA and RNA cancer diagnostic tests currently in use at Stanford Health Care as well as developing clinical algorithms using large-scale clinical laboratory datasets and patient electronic medical records to predict patient outcomes and aid in therapeutic clinical decision support. Additionally, Dr. Costa served as a co-Investigator in the NIH Clinical Genome Resource (ClinGen) Consortium, and led the engineering and product management teams developing FDA-recognized medical software applications used by healthcare providers, researchers, and biotechnology companies to define the clinical relevance of genes and pathogenicity of mutations identified in patients.
Dr. Costa is the founding director of the Stanford Clinical Data Science Fellowship where post-doctoral fellows engage in interdisciplinary clinical research and embed in health care workflows learning, building and deploying real-world health data solutions in the Stanford Health Care system. He is currently an Attending Medical Geneticist for the Molecular Genetic Pathology Laboratory at Stanford Health Care where he previously served as an Assistant Lab Director.
Dr. Costa received his BS in Genetics from University of California at Davis, his PhD in Genetics from Stanford University School of Medicine, and his ABMGG Clinical Molecular Genetics and Genomics fellowship training from Stanford University School of Medicine. -
Tina Cowan
Professor of Pathology (Clinical) and, by courtesy, of Pediatrics (Genetics)
Current Research and Scholarly Interestsscreening and diagnosis of patients with inborn errors of metabolism, including newborn screening, development of new testing methods and genotype/phenotype correlations.
-
Gerald Crabtree
David Korn, MD, Professor of Pathology and Professor of Developmental Biology
Current Research and Scholarly InterestsChromatin regulation and its roles in human cancer and the development of the nervous system. Engineering new methods for studying and controlling chromatin and epigenetic regulation in living cells.
-
Ronaldo da Silva Francisco Jr
Postdoctoral Scholar, Pathology
BioI am a geneticist focused on the application of computational and statistical methods to study genetic mechanisms of disease. My research interests include (i) genomic and precision medicine; (ii) detection and analysis of genetic variants using NGS data (WGS, WES, RNA-Seq); and (iii) transcriptome and allele-specific expression.
-
John W. Day, MD, PhD
Professor of Neurology, of Pediatrics (Genetics) and, by courtesy, of Pathology
On Partial Leave from 05/15/2023 To 06/15/2023Current Research and Scholarly InterestsOur Neuromuscular Division coordinates a comprehensive effort to conquer peripheral nerve and muscle disorders, including the muscular dystrophies, motor neuron disorders, neuromuscular junction abnormalities, and peripheral neuropathies. With patients and families foremost in mind, we have had success defining and combating these diseases, with research focused on identifying genetic causes, developing novel treatment, and maximizing patient function by optimizing current management.
-
Dylan Dodd
Assistant Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsHarnessing the gut microbiome to treat human disease.
-
Lawrence Eng
Professor (Research) of Pathology, Emeritus
Current Research and Scholarly InterestsAstrocytes make up a substantial proportion of the central nervous system (CNS) and participate in a variety of important physiologic and pathologic processes. They are characterized by vigorous response to diverse neurologic insults.
-
Edgar Engleman
Professor of Pathology and of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
-
Marcelo Fernandez Vina
Professor of Pathology (Research)
BioMarcelo Fernández-Viña, Ph.D., D (ABHI) is a Professor for the Department of Pathology at Stanford University Medical School and serves as Director of the Histocompatibility, Immunogenetics and Disease Profiling Laboratory at this institution. He has been working in the fields of Histocompatibility and Immunogenetics since 1982. He earned a degree in Biochemistry from the School of Basic Sciences in Rosario, Argentina, and his Ph.D. in Internal Medicine from the University of Buenos Aires Medical School in Argentina. Previously he held a position as a Professor in the Department of Laboratory Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. He has more than 180 peer reviewed publications, many of them focusing on HLA variation in multiple world populations, identifying susceptibility and resistance factors for diseases and in the impact of HLA mismatches in allogeneic transplantation; and 59 book chapters. He served as expert Consultant for Donor Searches for NMDP and as President Elect, President and Past President of the American Society for Histocompatibility and Immunogenetics. He served as a member of the Board of Directors and the Executive Committee for the United Network for Organ Sharing. He served as Co-Chair of the Immunobiology Committee of the CIBMTR; He also served as a member of the HHS Advisory Council on Blood Stem Cell Transplantation (ACBSCT).He serves as HLA Expert Consultant for the NMDP for the HRSA contract and is a member of the Histocompatibility Advisory Group for NMDP. He is Councilor of the International Histocompatibility Workshop and a member of the WHO Nomenclature Committee for Factors of the HLA System and was Chairman of the (17th) International HLA & Immunogenetics Workshop, and current President of the International HLA & Immunogenetics Workshop. He is Section Editor of Human Immunology and an Advisory Board Member of the International Journal of Immunogenetics and Bone Marrow Transplantation.
-
Sebastian Fernandez-Pol
Clinical Assistant Professor, Pathology
BioDr. Sebastian Fernandez-Pol is an academic hematopathologist with fellowship training in hematopathology and dermatopathology. He has a particular interest in improving diagnostic accuracy for cutaneous lymphoproliferative disorders. Dr. Fernandez-Pol received his B.A. in chemistry with a concentration in biochemistry from the Washington University in St. Louis in 2003, his MD and PhD from Northwestern University in 2013, and completed his anatomic pathology and clinical pathology residency, hematopathology fellowship, and dermatopathology fellowship at Stanford University in 2019.
-
Andrew Fire
George D. Smith Professor of Molecular and Genetic Medicine and Professor of Pathology and of Genetics
On Leave from 05/15/2023 To 06/25/2023Current Research and Scholarly InterestsWe study natural cellular mechanisms for adapting to genetic change. These include systems activated during normal development and those for detecting and responding to foreign or unwanted genetic activity. Underlying these studies are questions of how a cells can distinguish information as "self" versus "nonself" or "wanted" versus "unwanted".
-
Jelle Folkerts
Postdoctoral Scholar, Pathology
BioMy current endeavours focus on the identification of human mast cell degranulation regulators using a whole-genome CRISPR knockout library screen, and the validation of these findings using our recently developed technology platform. It is my long-standing goal to contribute to the design and development of specific and effective therapeutic interventions for mast cell-mediated diseases.
-
Ann Folkins
Associate Professor of Pathology
Current Research and Scholarly InterestsDr. Folkins' interest is in gynecologic and obstetric pathology, specifically in ovarian and endometrial malignancies and placental clinical-pathologic disorders.
-
Steven Foung
Professor of Pathology
Current Research and Scholarly InterestsOur research focus is define correlates of protection against hepatitis C virus and other viral pathogens. Detailed characterization of broadly neutralizing human or nonhuman primate monoclonal antibodies against these agents will create high-resolution, functional maps of linear and nonlinear epitopes comprising the major binding sites of both isolate-specific and broadly neutralizing antibodies for rational vaccine design.
